OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Raghav on Potential Combinations With Trastuzumab Deruxtecan in HER2+ CRC

January 28th 2022

Kanwal P.S. Raghav, MBBS, MD, discusses potential combinations with fam-trastuzumab deruxtecan-nxki in HER2-positive colorectal cancer.

Dr. LeBeau on the Potential Applicability of Shark Antibodies in Prostate Cancer

January 27th 2022

Aaron LeBeau, PhD, discusses the potential wide applicability of shark antibodies in developing imaging and therapeutic strategies in prostate cancer.

Dr. Gerds on Emerging Agents in Myelofibrosis

January 27th 2022

Aaron T. Gerds, MD, MS, discusses emerging agents in myelofibrosis.

Dr. Kopetz the Current State of ctDNA Testing in CRC

January 27th 2022

Edmund Scott Kopetz, MD, PhD, FACP, discusses the current state of circulating tumor DNA testing in colorectal cancer.

Dr. Mesa on the Unique Characteristics of Momelotinib in Myelofibrosis

January 26th 2022

Ruben A. Mesa, MD, discusses the unique characteristics of momelotinib in myelofibrosis.

Dr. Corr on the Utilization of Molecular Profiling in Endometrial Cancer

January 26th 2022

Bradley R. Corr, MD, discusses the utilization of molecular profiling in endometrial cancer.

Dr. Osarogiagbon on Geographic Disparities in Lung Cancer

January 26th 2022

Raymond U. Osarogiagbon, MD, FACP, discusses geographic disparities in lung cancer.

Dr. Patel on Optimizing Molecular Testing for EGFR Mutations in Lung Cancer

January 26th 2022

Sandip P. Patel, MD, discusses optimizing molecular testing for EGFR mutations in lung cancer.

Dr. Barzi on the Importance of Developing Novel Therapies in Metastatic CRC

January 26th 2022

Afsaneh Barzi, MD, PhD, discusses the importance of developing novel therapies in metastatic colorectal cancer.

Dr. Woloszynska on Continued Research Efforts Investigating Racial Disparities in Prostate Cancer

January 26th 2022

Anna Woloszynska, PhD, discusses continued research efforts investigating racial disparities in prostate cancer.

Dr. Lister on Selecting Patients With Lymphoma for CAR T-Cell Therapy

January 26th 2022

John Lister, MD, discusses selecting patients with lymphoma for CAR T-cell therapy.

Dr. Singhi on the Importance of Multidisciplinary Care With Pathologists in Cancer

January 25th 2022

Aatur D. Singhi, MD, PhD, discusses the importance of facilitating multidisciplinary conversations that include pathologists in cancer care.

Dr. Graham on the Role of the Pathologist in Biomarker Testing in Breast and GI Cancers

January 25th 2022

Rondell P. Graham, MBBS, discusses the role of the pathologist in biomarker testing for patients with breast and gastrointestinal cancers.

Dr. Factor on the Lack of Standardization in Biomarker Testing in Breast and GI Cancers

January 25th 2022

Rachel E. Factor, MD, MS, discusses the lack of standardization with biomarker testing in breast and gastrointestinal cancers.

Dr. Westin on Patient-Reported Outcomes From the TRANSFORM Study in R/R LBCL

January 24th 2022

Jason R. Westin, MD,discusses the patient-reported outcome data from the phase 3 TRANSFORM study in relapsed/ refractory large B-cell lymphoma.

Dr. Westin on the 2​-Year Follow-Up of the TRANSCEND-NHL-001 Trial in R/R LBCL

January 24th 2022

Jason R. Westin, MD, discusses the 2-year follow-up data of the ongoing phase 1 TRANSCEND-NHL-001 trial in relapsed/refractory large B-cell lymphoma.

Dr. Chandra on Evaluating Biological Differences in African Americans With Prostate Cancer

January 24th 2022

Dhyan Chandra, PhD, discusses evaluating biological differences between African American and Caucasian men with prostate cancer.

Dr. Gershenson on the Results of the MILO Trial in Low-Grade Serous Ovarian Cancer

January 24th 2022

David M. Gershenson, MD, discusses the results of the phase 3 MILO trial in low-grade serous ovarian cancer.

Dr. Galsky on Clinical Trials That Addressed Key Questions in Urothelial Cancer

January 24th 2022

Matthew Galsky, MD, discusses clinical trials that addressed key questions in urothelial cancer.

Dr. Oh on the Results of the TOPAZ-1 Trial in Advanced Biliary Tract Cancer

January 22nd 2022

Do-Youn Oh, MD, PhD, discusses the results of the phase 3 TOPAZ-1 trial in advanced biliary tract cancer.

NEXT PAGE
PREVIOUS PAGE